Endometriosis and Obstetric Outcomes
Endometriosis and Risk Factors in Pregnancy, Labor and Delivery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Carlo Alboni
- Phone Number: 0594224387
- Email: alboni.carlo@aou.mo.it
Study Locations
-
-
-
Modena, Italy, 41125
- Recruiting
- Carlo Alboni
-
Contact:
- Carlo Alboni, MD, PhD
- Phone Number: 0594224387
- Email: alboni.carlo@aou.mo.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnant women who delivered at Azienda Ospedaliero Universitaria Policlinico di Modena from 2000 to 2020
- Histologic diagnosis of endometriosis before pregnancy for case group
- Age matched healthy patients for control group
Exclusion Criteria:
- Clinical records not available
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with previous histologic diagnosis of endometriosis
|
Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
|
|
Patient without endometriosis
|
Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Preterm delivery
Time Frame: Time of delivery
|
Incidence of delivery before 37 weeks of pregnancy
|
Time of delivery
|
|
Gestational diabetes
Time Frame: after 18 weeks' pregnancy
|
fasting blood glucose >17 mmol/L
|
after 18 weeks' pregnancy
|
|
Gestational hypertension
Time Frame: after 20 weeks' gestation
|
blood pressure persistently > 140/90 mm Hg
|
after 20 weeks' gestation
|
|
Assisted reproduction technologies
Time Frame: before pregnancy
|
Patients who referred to assisted reproduction technologies
|
before pregnancy
|
|
Cesarean Section
Time Frame: Time of delivery
|
Robson Classifications
|
Time of delivery
|
|
Postpartum hemorrhage
Time Frame: Time of delivery
|
Greater than 500 mL estimated blood loss in a vaginal delivery or greater than 1000 mL estimated blood loss at the time of cesarean delivery
|
Time of delivery
|
|
Birth-weight
Time Frame: Time of delivery
|
small for gestational age (birth weight below the 10th percentile) or large for gestational age (birth weight over the 90th percentile)
|
Time of delivery
|
|
Apgar scores
Time Frame: Time of delivery
|
Apgar scores
|
Time of delivery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EndoPreg01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.